Last edition
News about "WuXi Biologics"
WuXi Biologics Signs Deal with Candid Therapeutics to Boost Trispecific T-cell Engager
Under the terms of the agreement, Candid will have exclusive global rights to a preclinical trispecific T-cell Engager discovered at WuXi Biologics' proprietary universal multispecific antibody platform WuXiBody.
WuXi Biologics | 07/01/2025 | By Aishwarya
WuXi Biologics, Boostimmune Ink MOU for Exclusive R&D Services
WuXi Biologics, Boostimmune Ink MOU for Exclusive R&D Services<br />
WuXi Biologics | 24/08/2023 | By Sudeep Soparkar | 360
Pharmadule Morimatsu and WuXi Biologics Reached Global Strategic Partnership
Pharmadule Morimatsu and WuXi Biologics Reached Global Strategic Partnership
WuXi Biologics | 28/06/2023 | By Sudeep Soparkar | 432
WuXi Biologics' drug substance and drug product facilities bags US FDA, EMA approval
These approvals add to the previous 25 certifications from more than 10 global regulatory administrations
WuXi Biologics | 20/09/2022 | By Sudeep Soparkar | 351
The facility has been successfully performing CMC projects for multiple clients since early 2022
WuXi Biologics | 20/07/2022 | By Sudeep Soparkar | 335
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy